Safety and efficacy of switching from clopidogrel to prasugrel in patients undergoing percutaneous coronary intervention: A study-level meta-analysis from 15 studies

Journal of Cardiovascular Pharmacology

Volumn 67, Issue 4, 2016, Pages 336-343

  Patti, Giuseppe ^a   Ricottini, Elisabetta ^a   De Luca, Leonardo ^b   Cavallari, Ilaria ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b EUROPEAN HOSPITAL   (Italy)

Author keywords

Antiplatelet drugs; Meta analysis; Percutaneous coronary intervention

Indexed keywords

CLOPIDOGREL; PRASUGREL; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ARTICLE; BLEEDING; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; HEART DISEASE; HUMAN; INCIDENCE; META ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; HEMORRHAGE; PROCEDURES;

DRUG SUBSTITUTION; HEMORRHAGE; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TICLOPIDINE;

EID: 84954450372     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000359     Document Type: Article

References (30)

1. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153:66.e9-16.
2. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27:1166-1173.
3. Angiolillo DJ, Badimon JJ, Saucedo JF, et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the optimizing anti-Platelet therapy in diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J. 2011;32:838-846.
4. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N EnglJ Med. 2007;357:2001-2015.
5. Angiolillo DJ, Saucedo JF, Deraad R, et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol. 2010;56:1017-1023.
6. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet Activation and Aggregation-Thrombolysis in Myocardial infarction 44 trial. Circulation. 2007;116:2923-2932.
7. De Luca G, Verdoia M, Schaffer A, et al. Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a singlecenter experience. J Thromb Thrombolysis. 2014;38:388-394.
8. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. Chichester, United Kingdom: John Wiley & Sons; 2005.
9. Alexopoulos D, Theodoropoulos KC, Stavrou EF, et al. Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction. Cardiovasc Drugs Ther. 2012;26:393-400.
10. Almendro-Delia M, Blanco Ponce E, Gomez-Domínguez R, et al. Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the "real world". J Thromb Thrombolysis. 2015;39:499-507.
11. Diodati JG, Saucedo JF, French JK, et al. Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary Syndrome patients (TRIPLET): a randomized controlled trial. Circ Cardiovasc Interv. 2013;6:567-574.
12. Dridi NP, Johansson PI, Clemmensen P, et al. Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response-the TAILOR (Thrombocytes and IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial. Platelets. 2014;25:506-512.
13. Kozinski M, Obonska K, Stankowska K, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. Cardiol J. 2014;21:547-556.
14. Lhermusier T, Lipinski MJ, Drenning D, et al. Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity. J Interv Cardiol. 2014;27:365-372.
15. Loh JP, Pendyala LK, Kitabata H, et al. Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2013;111:841-845.
16. Montalescot G, Sideris G, Cohen R, et al. Prasugrel compared with highdose clopidogrel in acute coronary syndrome. The randomised, doubleblind ACAPULCO study. Thromb Haemost. 2010;103:213-223.
17. Parodi G, De Luca G, Bellandi B, et al. Switching from clopidogrel to prasugrel in patients having coronary stent implantation. J Thromb Thrombolysis. 2014;38:395-401.
18. Sardella G, Calcagno S, Mancone M, et al. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial. Circ Cardiovasc Interv. 2012;5:698-704.
19. Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing platelet Reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with Prasugrel) study. J Am Coll Cardiol. 2012;59:2159-2164.
20. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
21. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
22. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
23. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-1101.
24. Aradi D, Tornyos A, Pintér T, et al. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol. 2014;63:1061-1070.
25. Brar SS, ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol. 2011;58:1945-1954.
26. Payne CD, Li YG, Brandt JT, et al. Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirintreated subjects. Platelets. 2008;19:275-281.
27. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2005;111:2099-2106.
28. Patti G, Grieco D, Dicuonzo G, et al. High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study. J Am Coll Cardiol. 2011;57:771-778.
29. Collet JP, Silvain J, Landivier A, et al. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the reload with clopidogrel before coronary Angioplasty in subjects treated long term with Dual Antiplatelet therapy (RELOAD) study. Circulation. 2008;118:1225-1233.
30. Verdoia M, Barbieri L, Suryapranata H, De Luca G. Switching from clopidogrel to prasugrel in patients undergoing PCI: a meta-analytic overview [published online August 19, 2015]. Platelets. 2015.